EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

New boronate drugs and evolving NDM-mediated beta-lactam resistance

Olga Lomovskaya iD, Ruslan Tsivkovski, Maxim Totrov, Dana Dressel, Mariana Castanheira, Michael Dudley

Antimicrobial Agents and Chemotherapy · 19.09.2023 · 67 (9)

DOI: 10.1128/aac.00579-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 19.09.2023. Verfasst von Olga Lomovskaya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Qpex Biopharma, Inc. , San Diego, California, USA. Hauptthemen laut MEDLINE: Borinic Acids. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | Biomedical Advanced Research and Development Authority (BARDA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Taniborbactam and xeruborbactam are dual serine-/metallo-beta-lactamase inhibitors (BLIs) based on a cyclic boronic acid pharmacophore that undergo clinical development. Recent report demonstrated that New Delhi metallo-beta-lactamase (NDM)-9 (differs from NDM-1 by a single amino acid substitution, E152K, evolved to overcome Zn (II) deprivation) is resistant to inhibition by taniborbactam constituting pre-existing taniborbactam resistance mechanism. Using microbiological and biochemical experiments, we show that xeruborbactam is capable of inhibiting NDM-9 and propose the structural basis for differences between two BLIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Borinic AcidsAmino Acid SubstitutionBoronic Acidsbeta-Lactam Resistancebeta-Lactamase InhibitorsCarboxylic Acids

Stichwörter der Autor:innen

NDMNDM-9metallo-β-lactamasetaniborbactamxeruborbactam

Substanzen

Borinic AcidsBoronic Acidsbeta-Lactamase InhibitorstaniborbactamCarboxylic Acids

Autor:innen und Institutionen

  • Qpex Biopharma, Inc. , San Diego, California, USA.
  • Molsoft, LLC , San Diego, California, USA.
  • IHMA, Inc. , Schaumburg, Illinois, USA.
  • JMI Laboratories , North Liberty, Iowa, USA.

ORCID-Profile: Olga Lomovskaya

Förderung

  • HHS | Biomedical Advanced Research and Development Authority (BARDA)

Zitieren

APA

Lomovskaya, O., Tsivkovski, R., Totrov, M., Dressel, D., Castanheira, M., & Dudley, M. (2023). New boronate drugs and evolving NDM-mediated beta-lactam resistance. Antimicrobial Agents and Chemotherapy, 67(9). https://doi.org/10.1128/aac.00579-23

Vancouver

Lomovskaya O, Tsivkovski R, Totrov M, Dressel D, Castanheira M, Dudley M. New boronate drugs and evolving NDM-mediated beta-lactam resistance. Antimicrobial Agents and Chemotherapy. 2023;67(9). doi:10.1128/aac.00579-23

BibTeX
@article{Lomovskaya2023,
  author = {Lomovskaya, Olga and Tsivkovski, Ruslan and Totrov, Maxim and Dressel, Dana and Castanheira, Mariana and Dudley, Michael},
  title = {New boronate drugs and evolving NDM-mediated beta-lactam resistance},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {9},
  doi = {10.1128/aac.00579-23}
}
Kostenlos starten →